NKTR Stock Analysis: Buy, Sell, or Hold?
NKTR - Nektar Therapeutics
$70.02
-1.33 (-1.86%)
▼
5d:
+1.97%
30d:
+10.01%
90d:
-19.27%
BUY
HIGH Confidence
Analysis Updated: Jul 28, 2026 12:00 AM ET
Earnings: Aug 06, 2026
8d
Smart Money Distribution
None View Scanner →
Strength: 5.7/10
Get Alerted When NKTR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NKTR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: NKTR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: NKTR is currently trading at $70.02, which is considered fair relative to its 30-day fair value range of $65.33 to $71.61.
Technical Outlook: Technically, NKTR is in a strong uptrend. Immediate support is located at $64.24, while resistance sits at $73.98.
Market Sentiment: NKTR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (13th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $153.22 (+114.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NKTR is in a strong uptrend. Immediate support is located at $64.24, while resistance sits at $73.98.
Market Sentiment: NKTR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (13th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $153.22 (+114.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$65.33 -
$71.61
Company Quality Score
59/100
(HOLD)
Options IV Signal
13th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 13th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 114.7% below Wall St target ($153.22)
Trading Range Analysis
30-Day Trading Range
$65.33 -
$71.61
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$6.51
(9.3%)
Support & Resistance Levels
Support Level
$64.24
Resistance Level
$73.98
Current Trend
Strong Uptrend
Technical data as of
Jul 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.01
Wall Street Target
$153.22
(+114.7%)
Revenue Growth (YoY)
3.8%
Profit Margin
-284.2%
Share & Embed Analysis
Last updated: July 28, 2026 3:36 PM ET
Data refreshes hourly during market hours. Next update: 4:36 PM
Data refreshes hourly during market hours. Next update: 4:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jonathan Zalevsky
SELL
180 shares
2026-02-18
Howard W Robin
SELL
423 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 49 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 54 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 51 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
